Clinerion Adds RWD RADAR to Patient Network Explorer
RWD RADAR generates patient cohort aggregate metrics, as well as offers metrics on the patient journey, from diagnosis to treatment modalities, and geographically, all based on real-world data available on Clinerion’s Patient Network Explorer platform. Patient cohort aggregate metrics show insights on disease-treatment relationships and disease-disease relationships, and are visualized as Top N lists, ranking the related concepts within a field code with the highest patient hits.
The statistics are based on real-time data and available with timestamps, allowing the generation of an incidence timeline. Data may be visualized aggregated, or geographically mapped, as well as showing gender and age distributions.
RWD RADAR can be used for epidemiology studies to look at disease occurrence, treatment metrics, differences by hospital, region, and country, as well as to identify differential treatment groups or cohorts by location, procedure or medication (segmentation by different treatment options and/or by drug/drug class).
Further developments under development by Clinerion include the installation of an infrastructure for deployment of artificial intelligence / machine learning algorithms.
For more information, click here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
